Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial.

Ann Rheum Dis · 2016 · PMC4752667 · PMID 25550338

Europe PMC DOI

hedged sentences

0.0750

closest p · 1.5× alpha

0.0790

boldest claim

The sentences

borderline significancep=0.075so close (0.05 < p ≤ 0.1)

During add-on therapy, that is, months 3–12, levels of all ACPAs showed greater declines among responders compared with non-responders, reaching statistical significance for anti-cVim (p=0.034) and anti-CCP IgG (p=0.025), and borderline significance for anti-CEP-1 IgG (p=0.075) ( figure 3 B).

also in 7,017 other papers

did not reach statistical significancep=0.079so close (0.05 < p ≤ 0.1)

This was also seen regarding antibodies to cFib (p=0.022), while the differences did not reach statistical significance regarding anti-CEP-1 and anti-cVim antibodies (p=0.079 and 0.13, respectively).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.